NECTIN4 and melanoma: NECTIN4-targeted therapy with ADCs, such as enfortumab vedotin, is a potential candidate for treating melanoma with BRAF-mutation and BRAFi-resistant melanomas, and its efficacy needs to be assessed in future research.